Epetraborole

Generic Name: Epetraborole

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₆BNO_₄

CAS Number: 1093643-37-8

Unique Ingredient Identifier: 6MC93Z2DF9

Background: Epetraborole has been used in trials studying the treatment of Infections, Bacterial, Infections, Intestinal, Infections, Urinary Tract, and Community-acquired Infection.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Spero's stock slides after antibiotic flops in Phase II trial

Spero Therapeutics halted development of antibiotic SPR720 after Phase IIa trial failure in NTM-PD patients, leading to 39% staff layoffs and a 17% stock drop. The company plans to focus on tebipenem HBr and SPR206, with tebipenem HBr out-licensed to GSK.

Related Clinical Trials:

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy